BACARDI
15.6.2022 13:02:07 CEST | Business Wire | Press release
Bacardi, the largest privately held spirits company in the world, has expanded its pioneering TAILS® COCKTAILS PROFESSIONAL range with new cocktails and a new look, available now for the hospitality industry across Western Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005150/en/
The premium batched cocktail brand offers the on-trade a hassle-free solution for serving quality cocktails easily, quickly and consistently at scale. Serving a TAILS cocktail takes as little as 15 seconds, and no specialist training is required.
The expanded range of classic and contemporary cocktails, all crafted using the Bacardi portfolio of premium brands has two new additions; the Whisky Sour , made with DEWAR’S® Blended Scotch whisky; and the Rum Punch , made with BACARDĺ® rum.
“Thousands of outlets across Europe are already enjoying a new revenue stream by serving TAILS COCKTAILS PROFESSIONAL, and this year we’re planning to more than double that number – the momentum is huge,” says Evert-Jan Bos, General Manager, TAILS COCKTAILS.
He adds: “With the new flavors, we’re catering for even more tastes and occasions – from summer terraces to cosy winter bars – offering an exciting opportunity for the hospitality industry to tap into the growing demand for cocktails.”
The expanded range also includes the Passion Fruit Martini Cocktail and Espresso Martini Cocktail , both made with 42BELOW® vodka; the Gin Garden Cocktail made with BOMBAY® Dry gin and ST-GERMAIN® elderflower liqueur; and the Classic Mojito and Berry Mojito , both made with BACARDĺ rum.
As well as the new-look 1L bottles, there are also three TAILS COCKTAILS PROFESSIONAL 20L kegs - the Passion Fruit Spritz made with 42BELOW® vodka, and the Classic Mojito and Caribbean Punch , both made with BACARDÍ rum – rolling out this summer, allowing outlets to serve cocktails on draught for even quicker, easier service.
With a full live music and events line-up back in Europe this year, Bacardi will also bring high quality cocktails to festivals at scale, with TAILS COCKTAILS PROFESSIONAL at more than 20 of the biggest festivals across the UK, Spain, Belgium and the Netherlands.
The range sits alongside the company’s recent launch of TAILS COCKTAILS , which takes TAILS into the off-trade for the first time, pioneering a new ‘ready-to-shake’ category within cocktails-at-home.
For more information, visit www.tailscocktails.com/professional .
Always drink responsibly
About the TAILS® COCKTAILS PROFESSIONAL range
TAILS COCKTAILS crafts expertly batched cocktails to ensure consistent quality and speed of service throughout the hospitality and events industry. Established in 2010, TAILS COCKTAILS was founded with a vision to make high-quality cocktails more accessible to a wider audience of cocktail lovers. Each TAILS cocktail begins with the highest quality, premium spirits – BACARDI® rum, 42BELOW® vodka, BOMBAY SAPPHIRE® gin, DEWAR’S® Blended Scotch whisky and ST-GERMAIN® elderflower liqueur – blended with top quality ingredients. The range is available in both 1L bottles and 20L kegs with draught pillars. The TAILS COCKTAILS brand is part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda. Visit www.tailscocktails.com/professional .
About Bacardi
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY® Dry gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded over 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005150/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom